Mindmed announces 2021 q2 financial results; cash balance of $157 usd million ($195 cad million) to execute on diverse clinical pipeline

New york, aug. 12, 2021 /prnewswire/ -- mindmed (nasdaq: mnmd), (neo: mmed), (de: mmq), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended june 30, 2021. q2 2021 financial highlights (in usd) total assets as of june 30, 2021 were $194 million, including $157 million in cash net cash used in operating activities of $12 million for the quarter ended june 30, 2021 net and comprehensive loss of $36 million for the quarter ended june 30, 2021 q2 2021 business highlights mindmed launched project angie, targeting the treatment of pain with psychedelics mindmed launched a collaboration with nextage therapeutics to explore applications of psychedelics in a brain targeting liposome delivery system mindmed and the liechti lab published the first pharmacogenetic data on lsd mindmed appointed dr. sarah vinson to its board of directors mindmed appointed drs.
MNMD Ratings Summary
MNMD Quant Ranking